CTLA4 and diabetes mellitus: Studies have shown that the majority of ICI-DM cases develop following treatment with PD-1 or PD-L1 inhibitors, rather than CTLA-4 inhibitors, indicating a potential link to the aberrant expression of PD-L1 by pancreatic β-cells.